CCN2 and neoplasm: Considering the fact that CTGF may serve as potential target (as currently studied in pancreatic cancer within a phase III trial: NCT03941093), further studies exploring the relevance of CTGF in the HNSCCs’ tumor microenvironment seem reasonable.